Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children

Joseph A. Church(University of Southern California), Prakash Sista, Elizabeth Smith(National Jewish Health), Coleen K. Cunningham(Duke Medical Center), Lynette Purdue(National Institutes of Health), Lynne Mofenson(Elizabeth Glaser Pediatric AIDS Foundation), Patricia DeLora, Elizabeth Hawkins(SUNY Upstate Medical University), Michael Hughes(Universitat Autònoma de Barcelona), Andrew Wiznia(Jacobi Medical Center), Paul Palumbo(Dartmouth College)
The Pediatric Infectious Disease Journal
July 1, 2002
10.1097/00006454-200207000-00010
Cited by 44

Related Papers

Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis
|BMJ|2020|2.4k
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
|The Lancet|1999|1.7k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1–Infected Women and Prevention of Perinatal HIV-1 Transmission
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2002|896